{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:28:26Z","timestamp":1777426106947,"version":"3.51.4"},"reference-count":65,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T00:00:00Z","timestamp":1413763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The major role of 24-hydroxylase (CYP24A1) is to maintain 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) homeostasis. Recently, it has been discovered that CYP24A1 also catalyses the hydroxylation of 20(OH)D3, producing dihydroxy-derivatives that show very effective antitumorigenic activities. Previously we showed a negative correlation of vitamin D receptor (VDR) and CYP27B1 expression with progression, aggressiveness and overall or disease-free survivals of skin melanomas. Therefore, we analyzed CYP24A1 expression in relation  to clinicopathomorphological features of nevi, skin melanomas and metastases. In melanocytic tumors, the level of CYP24A1 was higher than in the normal epidermis. The statistically highest mean CYP24A1 level was found in nevi and early stage melanomas. With melanoma progression, CYP24A1 levels decreased and in advanced stages were comparable to the normal epidermis and metastases. Furthermore, the CYP24A1 expression positively correlated with VDR and CYP27B1, and negatively correlated with mitotic activity. Lower CYP24A1 levels correlated with the presence of ulceration, necrosis, nodular type and amelanotic phenotypes. Moreover, a lack of detectable CYP24A1 expression was related to shorter overall and disease-free survival. In conclusion, the local vitamin D endocrine system affects melanoma behavior and an elevated level of CYP24A1 appears to have an important impact on the formation of melanocytic nevi and melanomagenesis, or progression, at early stages of tumor development.<\/jats:p>","DOI":"10.3390\/ijms151019000","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T10:14:47Z","timestamp":1413800087000},"page":"19000-19017","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["CYP24A1 Expression Inversely Correlates with Melanoma Progression: Clinic-Pathological Studies"],"prefix":"10.3390","volume":"15","author":[{"given":"Anna","family":"Bro\u017cyna","sequence":"first","affiliation":[{"name":"Department of Tumor Pathology and Pathomorphology, the Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-796 Bygoszcz, Poland"},{"name":"Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek \u0141ukaszczyk Memorial Hospital, 85-796 Bygoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cezary","family":"Jochymski","sequence":"additional","affiliation":[{"name":"Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek \u0141ukaszczyk Memorial Hospital, 85-796 Bygoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zorica","family":"Janjetovic","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"J\u00f3\u017awicki","sequence":"additional","affiliation":[{"name":"Department of Tumor Pathology and Pathomorphology, the Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-796 Bygoszcz, Poland"},{"name":"Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek \u0141ukaszczyk Memorial Hospital, 85-796 Bygoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Tuckey","sequence":"additional","affiliation":[{"name":"School of Chemistry and Biochemistry, the University of Western Australia, Crawley, WA 6009, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Slominski","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA"},{"name":"Division of Rheumatology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2014,10,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1210\/jc.2008-1454","article-title":"Nonclassic actions of vitamin D","volume":"94","author":"Bikle","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pbiomolbio.2006.02.014","article-title":"Vitamin D: Its role in cancer prevention and treatment","volume":"92","author":"Holick","year":"2006","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nrd3318","article-title":"Vitamin D, disease and therapeutic opportunities","volume":"9","author":"Plum","year":"2010","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.chembiol.2013.12.016","article-title":"Vitamin D metabolism, mechanism of action, and clinical applications","volume":"21","author":"Bikle","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1681\/ASN.V10122465","article-title":"Expression of 25-hydroxyvitamin D3-1\u03b1-hydroxylase in the human kidney","volume":"10","author":"Zehnder","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_7","first-page":"888","article-title":"Extrarenal expression of 25-hydroxyvitamin D3-1\u03b1-hydroxylase","volume":"86","author":"Zehnder","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1111\/febs.12862","article-title":"Kinetic analysis of human CYP24A1 metabolism of vitamin D via the C24-oxidation pathway","volume":"281","author":"Tieu","year":"2014","journal-title":"FEBS J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbapap.2010.06.022","article-title":"Cytochromes p450 are essential players in the vitamin D signaling system","volume":"1814","author":"Schuster","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1194\/jlr.R031534","article-title":"Cytochrome p450-mediated metabolism of vitamin D","volume":"55","author":"Jones","year":"2014","journal-title":"J. Lipid Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.abb.2011.11.003","article-title":"25-hydroxyvitamin D-24-hydroxylase (CYP24A1): Its important role in the degradation of vitamin D","volume":"523","author":"Jones","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-3-642-55580-0_14","article-title":"Importance of cytochrome p450-mediated metabolism in the mechanism of action of vitamin D analogs","volume":"164","author":"Masuda","year":"2003","journal-title":"Recent Results Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/1871520611009030213","article-title":"The vitamin D\/CYP24A1 story in cancer","volume":"10","author":"King","year":"2010","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_14","first-page":"119","article-title":"Metabolism of vitamin D3 by cytochromes p450","volume":"10","author":"Sakaki","year":"2005","journal-title":"Front. Biosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.clinbiochem.2012.07.110","article-title":"25(OH)D3 in patients with ovarian cancer and its correlation with survival","volume":"45","author":"Grabiec","year":"2012","journal-title":"Clin. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00520-014-2154-y","article-title":"Low 25-hydroxyvitamin D levels in people with a solid tumor cancer diagnosis: The tip of the iceberg?","volume":"22","author":"Hauser","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3390\/cancers5041439","article-title":"The inverse relationship between 25-hydroxyvitamin D and cancer survival: Discussion of causation","volume":"5","author":"Robsahm","year":"2013","journal-title":"Cancers"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1007\/s13277-013-0929-2","article-title":"Serum 25-hydroxyvitamin D and breast cancer risk: A meta-analysis of prospective studies","volume":"34","author":"Wang","year":"2013","journal-title":"Tumour Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4161\/derm.25244","article-title":"Vitamin D and melanoma","volume":"5","author":"Field","year":"2013","journal-title":"Dermatoendocrinology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0002-9440(10)63343-3","article-title":"Increased expression of 25-hydroxyvitamin D-1\u03b1-hydroxylase in dysgerminomas: A novel form of humoral hypercalcemia of malignancy","volume":"165","author":"Evans","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ecl.2010.02.010","article-title":"Vitamin D and the immune system: New perspectives on an old theme","volume":"39","author":"Hewison","year":"2010","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/1471-2407-10-483","article-title":"Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: A study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions","volume":"10","author":"Lopes","year":"2010","journal-title":"BMC Cancer"},{"key":"ref_23","first-page":"2683","article-title":"Expression analysis of CYP27B1 in tumor biopsies and cell cultures","volume":"26","author":"Radermacher","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/cbt.6.1.3493","article-title":"In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells","volume":"6","author":"Reichrath","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(00)04831-5","article-title":"25-hydroxyvitamin D-1\u03b1-hydroxylase in normal and malignant colon tissue","volume":"357","author":"Tangpricha","year":"2001","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.humpath.2012.03.031","article-title":"Expression of the vitamin D-activating enzyme 1alpha-hydroxylase (CYP27B1) decreases during melanoma progression","volume":"44","author":"Brozyna","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_27","first-page":"3635","article-title":"Expression of 25-hydroxyvitamin D3-24-hydroxylase in benign and malignant ovarian cell lines and tissue","volume":"29","author":"Fischer","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_28","first-page":"2015","article-title":"25-hydroxyvitamin D-1\u03b1-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate","volume":"28","author":"Chen","year":"2008","journal-title":"Anticancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.mam.2008.07.003","article-title":"Molecular actions of vitamin D contributing to cancer prevention","volume":"29","author":"Fleet","year":"2008","journal-title":"Mol. Aspects Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1210\/en.2011-0243","article-title":"Minireview: Vitamin D: Is there a role in extraskeletal health?","volume":"152","author":"Christakos","year":"2011","journal-title":"Endocrinology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1158\/1055-9965.EPI-05-0257","article-title":"Expression of vitamin D receptor and 25-hydroxyvitamin D3-1\u03b1-hydroxylase in normal and malignant human colon","volume":"14","author":"Matusiak","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/jcb.10342","article-title":"Prostatic 25-hydroxyvitamin D-1\u03b1-hydroxylase and its implication in prostate cancer","volume":"88","author":"Chen","year":"2003","journal-title":"J. Cell. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3691","article-title":"The role of vitamin D in reducing cancer risk and progression","volume":"14","author":"Feldman","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.3748\/wjg.v19.i17.2621","article-title":"CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells","volume":"19","author":"Kosa","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/18715206113139990307","article-title":"CYP24A1 as a potential target for cancer therapy","volume":"14","author":"Sakaki","year":"2014","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1096\/fj.13-236109","article-title":"Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies","volume":"28","author":"Lewis","year":"2014","journal-title":"FASEB J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.humpath.2010.09.014","article-title":"Expression of vitamin D receptor decreases during progression of pigmented skin lesions","volume":"42","author":"Brozyna","year":"2011","journal-title":"Hum. Pathol."},{"key":"ref_38","first-page":"2735","article-title":"Decreased VDR expression in cutaneous melanomas as marker of tumor progression: New data and analyses","volume":"34","author":"Brozyna","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/bjc.2011.458","article-title":"High basal NF-kappaB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives","volume":"105","author":"Janjetovic","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_40","first-page":"3733","article-title":"Novel vitamin D hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes","volume":"32","author":"Slominski","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.mayocp.2014.02.009","article-title":"Melanoma resistance: A bright future for academicians and a challenge for patient advocates","volume":"89","author":"Slominski","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00280-005-0059-7","article-title":"Expression of VDR and CYP24A1 mRNA in human tumors","volume":"57","author":"Anderson","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/eci.12176","article-title":"Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma","volume":"43","author":"Urbschat","year":"2012","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/annonc\/mdh056","article-title":"Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer","volume":"15","author":"Mimori","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1158\/1078-0432.CCR-10-1789","article-title":"CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma","volume":"17","author":"Chen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1369\/jhc.2009.954339","article-title":"The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis","volume":"58","author":"Horvath","year":"2010","journal-title":"J. Histochem. Cytochem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1369\/0022155412447296","article-title":"Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors","volume":"60","author":"Clinckspoor","year":"2012","journal-title":"J. Histochem. Cytochem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.bcp.2012.09.032","article-title":"Rat CYP24A1 acts on 20-hydroxyvitamin D3 producing hydroxylated products with increased biological activity","volume":"84","author":"Tieu","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1111\/j.1742-4658.2005.04819.x","article-title":"The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism","volume":"272","author":"Slominski","year":"2005","journal-title":"FEBS J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/j.1742-4658.2008.06406.x","article-title":"Pathways and products for the metabolism of vitamin D3 by cytochrome P450scc","volume":"275","author":"Tuckey","year":"2008","journal-title":"FEBS J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1096\/fj.12-208975","article-title":"In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1","volume":"26","author":"Slominski","year":"2012","journal-title":"FASEB J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jsbmb.2013.10.012","article-title":"The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions","volume":"144","author":"Slominski","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"C526","DOI":"10.1152\/ajpcell.00203.2010","article-title":"20-hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells","volume":"300","author":"Slominski","year":"2011","journal-title":"Am. J. Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1096\/fj.13-242040","article-title":"ROR\u03b1 and ROR\u03b3 are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D","volume":"28","author":"Slominski","year":"2014","journal-title":"FASEB J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1210\/endo.139.8.6185","article-title":"24,25-dihydroxyvitamin D-active metabolite or inactive catabolite?","volume":"139","author":"Glorieux","year":"1998","journal-title":"Endocrinology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1021\/bi962080i","article-title":"Synthesis, stereochemistry, and biological activity of 1\u03b1,23,25-trihydroxy-24-oxovitamin D3, a major natural metabolite of 1\u03b1,25-dihydroxyvitamin D3","volume":"36","author":"Lee","year":"1997","journal-title":"Biochemistry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jcb.20717","article-title":"24,25-dihydroxyvitamin D3 binds to catalase","volume":"97","author":"Larsson","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1152\/physrev.00044.2003","article-title":"Melanin pigmentation in mammalian skin and its hormonal regulation","volume":"84","author":"Slominski","year":"2004","journal-title":"Physiol. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1755-148X.2011.00898.x","article-title":"l-tyrosine and l-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions","volume":"25","author":"Slominski","year":"2012","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Slominski, A., Kim, T.K., Brozyna, A.A., Janjetovic, Z., Brooks, D.L., Schwab, L.P., Skobowiat, C., Jozwicki, W., and Seagroves, T.N. (2014). The role of melanogenesis in regulation of melanoma behavior: Melanogenesis leads to stimulation of HIF-1\u03b1 expression and HIF-dependent attendant pathways. Arch. Biochem. Biophys.","DOI":"10.1016\/j.abb.2014.06.030"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.humpath.2013.02.022","article-title":"Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma","volume":"44","author":"Brozyna","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00441-011-1216-4","article-title":"The analysis of receptor-binding cancer antigen expressed on siso cells (RCAS1) immunoreactivity within the microenvironment of the ovarian cancer lesion relative to the applied therapeutic strategy","volume":"345","author":"Jozwicki","year":"2011","journal-title":"Cell Tissue Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","article-title":"PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of braf melanoma cells","volume":"23","author":"Halaban","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e5988","DOI":"10.1371\/journal.pone.0005988","article-title":"20-Hydroxycholecalciferol, product of vitamin D3 hydroxylation by P450scc, decreases NF-\u03baB activity by increasing I\u03baB\u03b1 levels in human keratinocytes","volume":"4","author":"Janjetovic","year":"2009","journal-title":"PLoS One"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1242\/jcs.89.3.287","article-title":"Positive regulation of melanin pigmentation by two key substrates of the melanogenic pathway, l-tyrosine and l-dopa","volume":"89","author":"Slominski","year":"1998","journal-title":"J. Cell Sci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/15\/10\/19000\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:17:08Z","timestamp":1760217428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/15\/10\/19000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,20]]},"references-count":65,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10]]}},"alternative-id":["ijms151019000"],"URL":"https:\/\/doi.org\/10.3390\/ijms151019000","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,20]]}}}